UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN-LABEL, REGISTRATION DIRECTED PHASE 2 STUDY

Authors :: Wojciech Jurczak
Nilanjan Ghosh
James A. Reeves
Peter Sportelli
Jeffrey P. Sharman
John M. Burke
Michael S. Weiss
Ewa Lech-Marańda
P. L. Zinzani
H.P. Miskin
Bertrand Anz
Felipe Samaniego
Piotr Smolewski
C.Y. Cheah
Owen A. O'Connor
Nathan Fowler
Lori A. Leslie
Kathryn S. Kolibaba
Piers Em Patten
Julio C. Chavez
Lydia Scarfò
Enrico Derenzini
Source :: Hematological Oncology. 37:182-183
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Marginal zone lymphoma
Phases of clinical research
Hematology
General Medicine
Internal medicine
Relapsed refractory
medicine
In patient
Open label
business

Full Text Access

Tools